An Open-label, Single-arm, Multi-institutional Phase II Trial of Avelumab for Recurrent, Metastatic Nasopharyngeal Carcinoma
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Avelumab (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- 06 Jun 2017 According to trial design presented at 53rd Annual Meeting of the American Society of Clinical Oncology, the study has accrued two of planned thirty nine patients.
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 11 Oct 2016 Planned End Date changed from 1 Dec 2019 to 1 Sep 2020.